Core Viewpoint - Botao Bio announced the appointment of Dai Qi as the new sponsor representative for its ongoing supervision during the IPO process on the Sci-Tech Innovation Board, following a personnel change due to personal reasons of the previous representative [2] Group 1 - Botao Bio's IPO process is being supervised by Guotai Junan Securities, with the supervision period lasting until December 31, 2024 [2] - The company has not yet fully utilized the funds raised from the IPO, prompting continued oversight of the fund's storage and usage [2] - Dai Qi, the newly appointed sponsor representative, possesses substantial investment banking experience and is deemed capable of fulfilling the supervisory responsibilities [2]

证券日报网1月23日讯，博拓生物在接受调研者提问时表示，公司主业专注于POCT试剂及仪器的研 发、生产与销售，产品包括药物滥用检测、传染病检测、生殖健康检测、肿瘤标志物检测、心脏标志物 检测等系列，其中：药物滥用检测和传染病检测产品约占公司营收的80%。公司以海外销售为主，外销 对营收贡献率达75%左右。2025年受美国政府多轮关税政策影响，同时叠加传染病检测市场尤其是呼吸 道传染病、热带传染病的周期性波动等因素影响，公司营业收入下降较大，此外，研发费用和股份支付 费用等同比增加，公司业绩承受较大压力。在中美关税维持相对稳定的背景下，公司差异化竞争产品持 续出新，产品注册证书陆续获证，如2025年10月获FDA510(k)批准的芬太尼检测(OTC)、IVDR证书的陆 续获批以及微流控荧光免疫POCT产品在中国、欧盟及东南亚市场的陆续注册获证，公司有信心2026年 营业收入保持稳步增长。 ...

Group 1 - The core point of the article is that Botao Bio has announced a significant decrease in its expected net profit for the year 2025, projecting a net profit of approximately 45 million yuan, which represents a year-on-year decrease of about 73.45% [1] - The company anticipates a reduction of around 124.5155 million yuan compared to the previous year's legally disclosed data [1]

Core Viewpoint - Both Neuralink and Qingstone Yongjun are focused on invasive brain-machine interface technology, but they have distinct core objectives and approaches [1] Group 1: Company Comparison - Neuralink aims to create a comprehensive "whole-brain interface" that integrates multiple functions such as movement, language, and vision, with the ultimate goal of deep integration with artificial intelligence and achieving human-AI coexistence [1] - Qingstone Yongjun, on the other hand, concentrates on the vertical medical field, specifically targeting the treatment of treatment-resistant severe depression with its first product, which offers personalized treatment plans through a closed-loop control system [1] - The technological approach of Neuralink is characterized by platformization and generalization, while Qingstone Yongjun seeks to excel in specific brain disease treatment scenarios [1]

Core Viewpoint - The company has strategically invested in Hangzhou Haoshi Tianhui Technology Co., Ltd., acquiring a 16% stake as the sole investor in its latest financing round, marking another exploration in the non-invasive brain-computer interface sector following its 2025 investment in Qingshi Yongjuan [1] Group 1: Company Overview - Haoshi Tianhui is an innovative high-tech enterprise focused on artificial intelligence in the medical field, with a founding team that has overseas entrepreneurial experience and strong industry expertise [1] - The company has developed a diverse product matrix that includes applications in mental health, cardiovascular monitoring, and imaging diagnostics [1] Group 2: Product and Technology - Haoshi Tianhui's self-developed medical-grade non-invasive brain-computer interface and mental health assessment devices can accurately evaluate emotional issues such as depression and anxiety, integrating music therapy interventions into a comprehensive service model [1] - The products are designed for various settings, including hospitals, schools, health check centers, and mental health institutions, providing objective and efficient assessments compared to traditional evaluation methods [1] Group 3: Regulatory and Market Plans - The company obtained a Class II medical device registration certificate in November 2025 for its products aimed at detecting mental health issues, with plans to promote and sell these products in the domestic market starting in 2026 [1]

Core Viewpoint - The company plans to establish a specialized industry fund for brain-computer interfaces and brain science, with a total scale of 200 million yuan, to accelerate its strategic layout in this field [1] Group 1: Fund Details - The fund will be co-invested with professional investment institutions, with the company contributing 190 million yuan, accounting for 95% of the total committed capital [1] - The initial investment amount from the company is set at 50 million yuan, with the remaining contributions to be made based on project investment needs [1] Group 2: Investment Focus - The fund will target unlisted companies in the domestic and international brain-computer interface and brain science industry chain [1] - The aim is to enhance the company's industrial layout in brain-computer interfaces and neuroscience, promoting resource sharing and integration [1] Group 3: Strategic Goals - The fund seeks to achieve capital appreciation while serving the company's long-term strategic development goals [1] - The establishment of the fund is still pending approval from relevant authorities, and there are uncertainties regarding the smooth progress of investment projects [1]

证券日报网1月23日讯，博拓生物在接受调研者提问时表示，近期，青石永隽收到了国家基金委正式通 知，获国家自然科学基金联合基金生命健康重大专项《无支架高精度血管介入式脑机接口研究》资助， 批准直接经费额2，200万元，该项目属于国家自然科学基金委体系内的重大项目，青石永隽作为唯一企 业参与。 ...

Core Viewpoint - Botao Bio is forecasting a significant decline in net profit for 2025, with an expected net profit of approximately 45 million yuan, representing a year-on-year decrease of about 73.45% [1] Revenue Impact - The company's revenue is expected to be adversely affected in the first half of 2025 due to multiple tariff increases imposed by the U.S. government, leading to a decline in exports to the U.S. [1] - Domestic demand for respiratory testing products and mosquito-borne disease products in Latin America has also decreased year-on-year, further impacting overall revenue [1] Expense Impact - The company is focusing on innovation and team incentives, which has led to increased research and development expenses and costs associated with employee stock ownership plans [1] - Financial income from foreign exchange gains and interest has decreased year-on-year, contributing to a significant decline in profits [1] Non-Operating Income Impact - In the previous period, the company benefited from a $5 million advance payment and transportation fees from overseas customers for COVID-19 testing products, which were recognized as revenue in 2024, leading to increased net profit [1] - The current reporting period did not experience similar non-operating income, which has negatively affected profit figures [1]

现夏静波先生因个人原因发生工作变动，不能继续履行对公司的持续督导职责。 为保证持续督导工作的有序进行，国泰海通委派戴祺先生担任公司的保荐代表人 （戴祺先生简历参见附件），继续履行对公司的持续督导职责，戴祺先生具有较丰 富的投行工作经验，具备履职能力。本次保荐代表人变更后，公司首次公开发行股 票并在科创板上市的持续督导保荐代表人为沈强先生、戴祺先生。国泰海通及相关 保荐代表人将按照《证券发行上市保荐业务管理办法》《上海证券交易所科创板股 票上市规则》等有关规定，认真做好相关保荐工作的交接，切实履行持续督导职责。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 杭州博拓生物科技股份有限公司（以下简称"公司"）于近日收到国泰海通证 券股份有限公司（以下简称"国泰海通"）出具的《关于变更保荐代表人的函》。 国泰海通作为公司首次公开发行股票并在科创板上市的保荐机构，根据《证券 发行上市保荐业务管理办法》《上海证券交易所科创板股票上市规则》等有关规定， 原委派沈强先生、夏静波先生为该项目持续督导的保荐代表人。持续督导期限自首 次公开发 ...

证券代码：688767 证券简称：博拓生物 公告编号：2026-005 杭州博拓生物科技股份有限公司 2025 年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日。 （二）业绩预告情况 （1）经杭州博拓生物科技股份有限公司（以下简称"公司"）财务部门初 步测算，预计 2025 年年度实现归属于母公司所有者的净利润为 4,500.00 万元左 右，与上年同期（法定披露数据）相比，将减少 12,451.55 万元左右，同比减少 73.45%左右。 （2）归属于母公司所有者的扣除非经常性损益的净利润为 2,400.00 万元左 右，与上年同期（法定披露数据）相比，将减少 9,528.76 万元左右，同比减少 79.88%左右。 二、上年同期业绩情况 （一）营业收入影响 2025 年上半年，由于美国政府多次加征关税引发全球市场重大波动，公司 对美出口下滑；受周期性波动影响，国内呼吸道检测产品以及拉美地区登革热等 ...